C
COMPASS Pathways plc (CMPS)
NMS – Real Time Price. Currency in USD
5.37
-0.27 (-4.79%)
At close: Mar 27, 2026, 4:00 PM EDT
5.54
+0.17 (3.17%)
After-hours: Mar 27, 2026, 6:41 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
5.37
-0.27 (-4.79%)
At close: Mar 27, 2026, 4:00 PM EDT
5.54
+0.17 (3.17%)
After-hours: Mar 27, 2026, 6:41 PM EDT
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Name | Position |
|---|---|
| Dr. Guy Goodwin | Chief Medical Officer |
| Dr. Michael Gold M.D., M.Sc. | Chief Research & Development Officer |
| Dr. Steve Levine M.D. | Chief Patient Officer |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Mr. Benjamin Harber | Company Secretary |
| Mr. Kabir Kumar Nath M.A., M.B.A. | CEO & Director |
| Mr. Lars Christian Wilde | Senior Advisor |
| Mr. Stephen D. Schultz |
| Date | Type | Document |
|---|---|---|
| 2026-01-07 | 8-K | cmps-20260105.htm |
| 2025-11-04 | 8-K | cmps-20251104.htm |
| 2025-10-29 | 8-K | cmps-20251026.htm |
| 2025-07-31 | 8-K | cmps-20250731.htm |
| 2025-07-29 | 8-K | cmps-20250728.htm |
| 2025-06-23 | 8-K | cmps-20250623.htm |
| 2025-06-13 | 8-K | cmps-20250612.htm |
| 2025-05-08 | 8-K | cmps-20250508.htm |
| 2025-05-05 | CORRESP | filename1.htm |
| 2025-04-28 | ARS | a2024ars.htm |
| Senior Vice President of Investor Relations |
| Ms. Lori Englebert M.B.A. | Chief Commercial Officer |
| Ms. Teri Loxam M.B.A. | CFO, Principal Financial Officer & Principal Accounting Officer |